Purpose: Benign prostatic hyperplasia (BPH) is a histologic diagnosis describing
proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The …

Current Treatment for Benign Prostatic Hyperplasia - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …

Objectives To describe the trend in the impact of lower urinary tract symptoms attributed to
benign prostatic hyperplasia (LUTS/BPH) on a global scale using the Global Burden of …

Purpose Clinicians use tamsulosin, an α1‐adrenoceptor antagonist, to manage symptomatic
benign prostatic hyperplasia (BPH). Because α1‐adrenoceptors are also present in the …

Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of
inhibitors of 5α‐reductase (5 ARI s) is limited by their association with adverse sexual side …

Background Adrenergic alpha-1 receptor antagonists (alpha-1 antagonists) are frequently
used medications in the management of lower urinary tract symptoms (LUTS) suggestive of …

Introduction Benign prostatic hyperplasia (BPH) represents the histological entity of prostate
cell proliferation, which inflicts a gradually increasing obstruction of the bladder outlet and is …

Objective Our chief objective was to assess whether longer duration of 5α-RI exposure
increases risk of PED, independent of age and other known risk factors. Men with shorter 5α …

Background A variety of alpha‐blockers are used for treating lower urinary tract symptoms
(LUTS) in men with benign prostatic hyperplasia (BPH). Silodosin is a novel, more selective …

BACKGROUND/OBJECTIVES To estimate associations between lower urinary tract
symptoms (LUTS) and phenotypic frailty in older men. DESIGN Cross‐sectional study …